Phase II trial of VIPER [bortezomib + dexamethasone + ifosfamide + cisplatin + etoposide + rituximab] chemotherapy in relapsed and refractory diffuse large B-cell lymphoma (NHL) [non-Hodgkin's lymphoma].

Trial Profile

Phase II trial of VIPER [bortezomib + dexamethasone + ifosfamide + cisplatin + etoposide + rituximab] chemotherapy in relapsed and refractory diffuse large B-cell lymphoma (NHL) [non-Hodgkin's lymphoma].

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Bortezomib; Cisplatin; Dexamethasone; Etoposide; Ifosfamide; Mesna; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Jan 2008 The expected completion date for this trial is now 1 Dec 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top